Altimmune Shares Findings on Pemvidutide's Impact on Cardioinflammatory Lipid Levels at ADA’s 84th Annual Scientific Sessions.

Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.

In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.

Sun Pharma's GL0034 (Utreglutide) Showcases Remarkable Weight Loss and Metabolic Improvements in Obesity at ADA's 84th Session.

Takeda Reveals New Data from Phase 2b Study of Mezagitamab, Showing Potential to Innovate Primary Immune Thrombocytopenia Treatment.

Bristol Myers Squibb's application for subcutaneous nivolumab has been validated by the European Medicines Agency.

argenx Reveals FDA Nod for VYVGART Hytrulo in Treating Chronic Inflammatory Demyelinating Polyneuropathy.

Takeda has revealed that the European Commission has given its approval for FRUZAQLA (fruquintinib) to be used as a monotherapy for adult patients suffering from metastatic colorectal cancer.

Bristol Myers Squibb reveals that the U.S. FDA has granted accelerated approval for KRAZATI® (adagrasib) combined with Cetuximab for adults with previously treated, advanced, or metastatic colorectal cancer (CRC) with the KRAS G12C mutation.

Zealand Pharma reveals favorable topline outcomes from the 16-week Phase 1b trial with escalating doses of long-acting amylin analog petrelintide.

Kyverna's KYV-101 gets U.S. FDA IND approval for treating patients with hard-to-treat Stiff-Person Syndrome in the KYSA-8 Phase 2 study.

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease.